Stock Price & Analysis

Analysis and Insights

Technical Analysis:

BIO stock is currently trading at $247.76, with oversold conditions indicated by an RSI of 23.93. The MACD is bearish, but the stock is approaching a critical Fibonacci resistance level of 276.98. A breakout above this level could signal a trend reversal.

Valuation and Analyst Sentiment:

BIO is part of an ETF with a 22.72% upside target, and analysts have set a price target of $481, indicating a 40.38% potential increase. This suggests strong confidence in BIO's recovery and growth.

Conclusion:

Given the oversold conditions and positive analyst outlook, BIO stock presents a buying opportunity. The stock is undervalued with potential for growth, especially if it breaks above the resistance level.

The price prediction for BIO stock in 2025 is $481, driven by strong analyst sentiment and a "Strong Buy" consensus. Analysts expect a 40.38% upside from current levels.

The S1 support level for BIO Stock is $246.32 ,The R1 resistant level for BIO Stock is $265.65.

As of the end of day on 2025-03-14, the price of BIO Stock was $246.01.

The target price for BIO Stock according to analyst rating is 374.00, with the highest price target at 447.00 and the lowest at 320.00. Analysts have a Moderate Buy rating on BIO Stock overall.

The market cap of BIO is $6.9B.

Analysis and Insights

To determine if BIO is overvalued, we analyze its valuation metrics, financial performance, and market sentiment.

Valuation Metrics:

BIO's valuation metrics indicate a premium relative to its peers. The stock trades at a P/E ratio of 18.19x (Q3 2024) and 19.37x (Q4 2024), with an EV/EBITDA of 3.69x and 3.61x, respectively. The P/S ratio is 1.25x and 1.40x, while the P/B ratio is 6.14x and 6.48x. These metrics suggest a higher valuation compared to industry averages.

Financial Performance:

BIO reported total revenue of $649.729M (Q3 2024) and $667.475M (Q4 2024), showing moderate growth. However, net income declined significantly to -$715.802M in Q4 2024, raising concerns about profitability. Gross margin decreased to 51.22% in Q4, and net margin turned negative at -24.09%, indicating margin compression.

Market Sentiment and Analyst Outlook:

Despite the stock's recent 8.12% drop, analysts maintain a "Buy" rating with a price target of $481, implying a 40.38% upside. However, technical indicators such as RSI (23.93) and MACD (-20.47) suggest the stock is oversold, potentially indicating a short-term rebound opportunity.

Conclusion:

BIO appears overvalued given its high valuation multiples, declining profitability, and negative margins. While analyst sentiment remains positive, investors should exercise caution and consider waiting for a correction or improved financial performance before investing.

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Price Prediction for BIO Stock by 2030

Based on current trends and analyst projections, BIO stock is predicted to reach $500 by 2030. This forecast is supported by strong analyst targets, with RBC Capital setting a $481 price target, indicating a 40.38% upside from its current price of $247.76. The company's position in the growing life sciences sector and improving revenue trends further bolster this outlook.

BIO has a total of 8030 employees.